CRF1R Inhibitors
1 drugsAbout CRF1R
Corticotropin-releasing factor receptor 1 (CRF1R) is a GPCR mediating the body's stress response via the hypothalamic-pituitary-adrenal (HPA) axis. Activated by corticotropin-releasing factor (CRF), it triggers hormonal and neuronal events. Dysregulation of the HPA axis implicates CRF1R in various conditions.
CRF1R is a compelling drug target due to its role in stress-related disorders. Currently, there is no genetic evidence available linking CRF1R to specific diseases. Further research is needed to explore the therapeutic potential of CRF1R modulation.
CRF1R is targeted by one FDA-approved drug, CRENESSITY (Neurocrine Biosciences), a small molecule. CRENESSITY has one indication in the 'other' therapeutic area. Further investigation into the mechanisms and downstream effects of CRF1R modulation is warranted to fully realize its therapeutic potential.
Top CRF1R Drugs
The competitive landscape is dominated by Neurocrine Biosciences, the sole company with an approved CRF1R drug.
High market concentration suggests significant entry barriers; consider strategic partnerships or niche indications to gain market access.
CRF1R Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets CRF1R, using small molecule modality.
Explore opportunities for novel modalities like antibodies or peptides to differentiate from existing small molecule approaches.
CRF1R Clinical Trials 5 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on CRF1R. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 3 | 1 | 0 | 2 | 100% |
| Phase 3 | 2 | 0 | 0 | 2 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
CRF1R Drug Approval Timeline (2024 - 2024)
The first and most recent drug approval for CRF1R was CRENESSITY in 2024.
Recent approval indicates renewed interest in CRF1R; monitor clinical trials and emerging data to assess future opportunities.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 2 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on CRF1R. A trial counts if an approved drug acting on CRF1R is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.